Zacks Investment Research on MSN
Is BMY's deep pipeline the key to its next growth phase?
Bristol Myers Squibb BMY highlighted the potential of its deep and promising pipeline at the 44th Annual J.P. Morgan ...
A groundbreaking study reveals that sacituzumab govitecan and pembrolizumab significantly enhance survival in untreated metastatic triple-negative breast cancer patients.
The FDA's Fast Track designation helps to accelerate the development and review of products for serious and life-threatening conditions.
Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT(TM) (cosibelimab-ipdl). UNLOXCYT is the first ...
DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ResearchAndMarkets ...
PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results